Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2014

Originalarbeiten


  • Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 164(2):258-65 (2014)
  • Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, Klimm B, Diehl V, Sasse S, Rothe A, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG). Blood 13;123(11):1658-64 (2014)
  • Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M. Significant dose escalation of Idarubicin in the treatment of aggressive non Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. Study Protocol. SpringerPlus Jan 3:5 (2014)
  • Hansen HP, Engels HM, Dams M, Paes Leme AF, Pauletti BA, Simhadri VL, Dürkop H, Reiners KS, Barnert S, Engert A, Schubert R, Quondamatteo F, Hallek M, Pogge von Strandmann E. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin’s lymphoma. J Pathol 232(4):405-14 (2014)
  • Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M. The assessment of tumor size reduction improves outcome prediction of PET/CT after chemotherapy in advanced stage Hodgkin Lymphoma. J Clin Oncol 32;17(10):1776-81 (2014)
  • Gandhi M, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN. Pancreatitis in patients treated with Brentuximab Vedotin: a previously unrecognized serious adverse event. Letter to the editor. Blood 123(18):2895-7 (2014)
  • Harrison SJ, Hsu A, Neeson P, Younes A, Sureda A, Engert A, Prince HM, Li M, Savage P, Bugarini R, Williams D, Squier M, Ritchie D. Early TARC reduction and response following Panobinostat treatment in patients with relapsed/refractory Hodgkin’s lymphoma following autologous stem cell transplant. Leuk Lymphoma 55(5):1053-1060 (2014)
  • Hartmann S, Eichenauer DA, Plütschow A, Mottok A, Roshanak B, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller AC, Ott G, Möller P, Rosenwald A, Stein H, Hansmann ML, Engert A, Klapper W. Histopathologic features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma – a matched pair anaysis form the German Hodgkin Study Group (GHSG). Br J Haematol Jun 26 (2014) [Epub ahead of print]
  • Coutelle O, Büning H, Plütschow A, Fuchs M, Escalona-Espinosa L, Engert A, Hacker U. Prognostic serum cytokines in classical Hodgkin lymphoma--letter. Clin Cancer Res. 2014 Dec 15;20(24):6633.
  • Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer. 2014 Jun 15;134(12):2829-40.
  • von Tresckow B, Müller H, Eichenauer DA, Glossmann JP, Josting A, Böll B, Klimm B, Sasse S, Fuchs M, Borchmann P, Engert A. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant. Leuk Lymphoma. 2014 Aug;55(8):1922-4.

Übersichtsarbeiten


  • Eichenauer D, Engert A. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma. Eur J Hematol Jul;93(1):1-8 (2014)
  • Rancea M, von Tresckow B, Monsef I, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin Lymphoma: a systematic review with meta-analysis. Crit Rev Oncol Hematol May 2 (2014) [Epub ahead of print]
  • Sasse S, Behringer K, Semrau R, Engert A. Kontroversen in der Behandlung früher und mittlerer Stadien des klassischen Hodgkin Lymphoms. Themenheft “Hodgkin Lymphom”. Der Onkologe 20(5):448-456 (2014)
  • Von Tresckow B, Engert A. Brentuximab Vedotin: ein neuer, zielgerichteter Ansatz zur Behandlung rezidivierter oder refraktärer Patienten. Themenheft “Hodgkin Lymphom”. Der Onkologe 20(5):464-9 (2014)
  • Engert A. Therapiealgorithmus für Patienten mit Hodgkin Lymphom. Themenheft “Hodgkin Lymphom”. Der Onkologe 20(5):420 (2014)
  • Engert A, Höffken K. Hodgkin Lymphom – Eine Erfolgsgeschichte. Editorial. Themenheft “Hodgkin Lymphom”. Der Onkologe 20(5):418-9 (2014)
  • Bergenthal N, Will A, Streckmann F, Wolkewitz KD, Monsef I, Engert A, Elter T, Skoetz N. Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev. 2014 Nov 11;11:CD009075.
  • Jachimowicz RD, Engert A. The challenging aspects of managing adolescents and young adults with Hodgkin's lymphoma. Acta Haematol. 2014;132(3-4):274-8.
  • Lohr F, Georg D, Cozzi L, Eich HT, Weber DC, Koeck J, Knäusl B, Dieckmann K, Abo-Madyan Y, Fiandra C, Mueller RP, Engert A, Ricardi U. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open? Strahlenther Onkol. 2014 Oct;190(10):864-6, 868-71.
  • Rancea M, Will A, Borchmann P, Monsef I, Engert A, Skoetz N. Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma. J Natl Cancer Inst. 2014 Jul 16;106(8).
  • Zacher J, Kasenda B, Engert A, Skoetz N. The role of additional radiotherapy for primary central nervous system lymphoma. Cochrane Database Syst Rev. 2014 Jun 16;6:CD009211.
  • Felbel S, Meerpohl JJ, Monsef I, Engert A, Skoetz N. Yoga in addition to standard care for patients with haematological malignancies. Cochrane Database Syst Rev. 2014 Jun 12;6:CD010146.